1) Rothschild B M, et al:Symmetrical erosive peripheral polyarthritis in the late archaic period of Alabama. Science 24:1498-1502, 1988.
2) Winchester R J:The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 56:389-466, 1994.
3) Gregersen P K, et al The shared epitope hypothesis an approach to understanding the molecular genetics of susceptibdity to rheumatoid arthritis. Arthritis Rheum 30:1205-1213, 1987.
4) 斉藤輝信, 他:日本リウマチ財団教育研修会テキスト4版. p319-330. 1999.
5) Weinblatt M E, et al:Methotrexate in rheumatoid arthritis. A five-year prospective multicenter trial. Athritis Rheum 3:1492-1498, 1994.
6) Lopez-Mendez A, et al:Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic disease program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 36:1364-1369, 1993.
7) Gutierrez-Urena S, et al:Pancytopenia secondariy to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272-276, 1996.
8) Kremer J M, et al:Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37:316, 1994.
9) Kirwan J R, et al:The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142-146, 1995.
11) Weinblatt M E, et al:Atrial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259, 1999.